NCT Number: NCT00265551
Study Evaluating SCA-136 in Subjects With Acute Exacerbations of Schizophrenia
The purpose of this study is to determine whether a low dose and a high dose of the study drug SCA-136 are effective and safe in the treatment of schizophrenia requiring hospitalization.
Looking for future studies?
Notify MeKey information
Age range
18 year–65 year
Sex eligibility
All sexes
Study type
Interventional
Phase
Phase 2
Primary location
Little Rock, Arkansas, United States
Who can participate
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
- Clinical diagnosis of schizophrenia
- Ability to remain hospitalized for at least first 4 weeks of study
- Needs hospitalization due to worsening of schizophrenia
Exclusion criteria
- Type 1 or 2 diabetes
- Previous use of clozapine
- Serious medical illness other than schizophrenia
Treatment and study plan
SCA-136 (400 mg)
Drugolanzapine (15 mg)
DrugPlacebo
DrugPrimary outcomes
-
Change from baseline to day 42 on the positive subscale of the SCI-PANNS
Secondary outcomes
-
Change from baseline to day 42 on:
-
SCI-PANNS total score
-
negative symptom sub-scale score of SCI-PANNS
-
general psychopathology subscale score of SCI-PANNS
-
response rate based upon SCI-PANNS total score
-
BPRS score
-
CGI-S score
-
CGI-I score
-
Cognitive assessments scores
Sponsors and collaborators
Lead sponsor
Wyeth is now a wholly owned subsidiary of Pfizer
Industry
Registry information
Official study title
A Randomized, Double-Blind, Placebo-Controlled, Olanzapine-Referenced, Parallel Group Safety, Efficacy, and Tolerability Study of SCA-136 in Subjects With Acute Exacerbations of Schizophrenia
Important dates
- Study start
- 2006
- Study completion
- 2007
- First posted
- Dec 14, 2005
- Registry last updated
- Dec 10, 2007
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Related clinical trials
Published trials that share one or more normalized conditions with this study.
Magnetic Resonance Imaging (MRI) of Neuropsychiatric Patients and Healthy Volunteers
NCT00004571
Mental Disorders, Normal Physiology
Bethesda, Maryland, United States
View Trial DetailsTele-group Cognitive Behavioural Family Intervention for People With Schizophrenia and Their Families (Feasibility tgCBFI)
NCT05808244
Mental Disorders, Psychosis
Kowloon, Hong Kong
View Trial DetailsPersonalized and Scalable Cognitive Remediation Approaches
NCT01945333
Mental Disorders, Psychotic Disorders
Brooklyn, New York, United States
View Trial DetailsInpatient Evaluation of Adults With Schizophrenia
NCT00001247
Mental Disorders, Psychotic Disorders
Bethesda, Maryland, United States
View Trial Details